• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical course and outcomes of patients with asthma hospitalized for severe acute respiratory syndrome coronavirus 2 pneumonia: A single-center, retrospective study.

作者信息

Lombardi Carlo, Roca Elena, Bigni Barbara, Cottini Marcello, Passalacqua Giovanni

机构信息

Asthma Center and COVID Unit, Departmental Unit of Allergology, Immunology, and Pneumology, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy; COVID Unit, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.

COVID Unit, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.

出版信息

Ann Allergy Asthma Immunol. 2020 Dec;125(6):707-709. doi: 10.1016/j.anai.2020.07.029. Epub 2020 Aug 1.

DOI:10.1016/j.anai.2020.07.029
PMID:32745609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7395222/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd7f/7395222/59d08ec9ae38/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd7f/7395222/59d08ec9ae38/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd7f/7395222/59d08ec9ae38/gr1_lrg.jpg

相似文献

1
Clinical course and outcomes of patients with asthma hospitalized for severe acute respiratory syndrome coronavirus 2 pneumonia: A single-center, retrospective study.因严重急性呼吸综合征冠状病毒2型肺炎住院的哮喘患者的临床病程及结局：一项单中心回顾性研究。
Ann Allergy Asthma Immunol. 2020 Dec;125(6):707-709. doi: 10.1016/j.anai.2020.07.029. Epub 2020 Aug 1.
2
Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana.多变量 COVID-19 死亡率分析：比较路易斯安那州的癌症患者和非癌症患者。
Cancer. 2021 Jan 15;127(2):266-274. doi: 10.1002/cncr.33243. Epub 2020 Oct 28.
3
Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.为何 COVID-19 患者的哮喘发病率较低，这证明了将 EDTA 溶液重新用于预防和治疗 COVID-19 疾病是合理的。
Med Hypotheses. 2020 Nov;144:110027. doi: 10.1016/j.mehy.2020.110027. Epub 2020 Jun 26.
4
Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: A retrospective study from a single center.新型冠状病毒肺炎与疑似且确诊的新型冠状病毒肺炎阴性肺炎的差异：一项来自单一中心的回顾性研究。
J Med Virol. 2020 Sep;92(9):1572-1579. doi: 10.1002/jmv.25810. Epub 2020 Jun 12.
5
Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation.需要住院的 COVID-19 肺炎合并哮喘患者的特征和结局。
Eur Respir J. 2020 Nov 5;56(5). doi: 10.1183/13993003.01875-2020. Print 2020 Nov.
6
Trisomy 21 and Coronavirus Disease 2019 in Pediatric Patients.21 三体综合征与儿童 2019 冠状病毒病。
J Pediatr. 2021 Jan;228:294-296. doi: 10.1016/j.jpeds.2020.08.067. Epub 2020 Aug 27.
7
Asthma exacerbation associated with COVID-19 pneumonia.与新型冠状病毒肺炎相关的哮喘加重
Allergol Int. 2021 Jan;70(1):129-130. doi: 10.1016/j.alit.2020.07.002. Epub 2020 Jul 27.
8
Prevalence, Characteristics, and Outcome of Asthmatic Patients With Type 2 Diseases in Hospitalized Patients With COVID-19 in Madrid, Spain.西班牙马德里新冠肺炎住院患者中合并2型疾病的哮喘患者的患病率、特征及结局
J Investig Allergol Clin Immunol. 2020;30(5):382-384. doi: 10.18176/jiaci.0627. Epub 2020 Jun 18.
9
[Prevalence of asthma in patients hospitalized for pneumonia associated to SARS-CoV-2 infection].[因新型冠状病毒肺炎住院患者中哮喘的患病率]
Rev Alerg Mex. 2023 May 24;70(1):1-7. doi: 10.29262/ram.v70i1.1175.
10
COVID-19 Susceptibility in Bronchial Asthma.COVID-19 易感性与支气管哮喘。
J Allergy Clin Immunol Pract. 2021 Feb;9(2):684-692.e1. doi: 10.1016/j.jaip.2020.11.020. Epub 2020 Nov 24.

引用本文的文献

1
Longitudinal Analysis of Pulmonary Function Impairment One Year Post-COVID-19: A Single-Center Study.新冠病毒感染后一年肺功能损害的纵向分析：一项单中心研究
J Pers Med. 2023 Jul 26;13(8):1190. doi: 10.3390/jpm13081190.
2
Effect of asthma, COPD, and ACO on COVID-19: A systematic review and meta-analysis.哮喘、COPD 和 ACO 对 COVID-19 的影响：系统评价和荟萃分析。
PLoS One. 2022 Nov 1;17(11):e0276774. doi: 10.1371/journal.pone.0276774. eCollection 2022.
3
Comparison between clinical characteristics and laboratory findings among patients with complicated and noncomplicated SARS-CoV-2 infection: A single-center experience from Shebin Al-Kom, Egypt.

本文引用的文献

1
Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2.呼吸道过敏、哮喘与新型冠状病毒受体血管紧张素转换酶2表达的关联。
J Allergy Clin Immunol. 2020 Jul;146(1):203-206.e3. doi: 10.1016/j.jaci.2020.04.009. Epub 2020 Apr 22.
2
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区，5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
3
Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?
比较埃及谢宾·阿尔科姆单一中心患者中伴有和不伴有 SARS-CoV-2 感染并发症的临床特征和实验室检查结果。
Immun Inflamm Dis. 2022 Aug;10(8):e671. doi: 10.1002/iid3.671.
4
Asthma and coronavirus disease 2019-related outcomes in hospitalized patients: A single-center experience.住院患者的哮喘和 2019 冠状病毒病相关结局：单中心经验。
Ann Allergy Asthma Immunol. 2022 Jul;129(1):79-87.e6. doi: 10.1016/j.anai.2022.03.017. Epub 2022 Mar 24.
5
Recent advances and developments in COVID-19 in the context of allergic diseases.新冠病毒肺炎在过敏性疾病背景下的最新进展与动态
Clin Transl Allergy. 2021 Sep;11(7):e12065. doi: 10.1002/clt2.12065.
6
Risk, Mechanisms and Implications of Asthma-Associated Infectious and Inflammatory Multimorbidities (AIMs) among Individuals With Asthma: a Systematic Review and a Case Study.哮喘患者中哮喘相关感染性和炎症性多重疾病（AIMs）的风险、机制及影响：一项系统评价和病例研究
Allergy Asthma Immunol Res. 2021 Sep;13(5):697-718. doi: 10.4168/aair.2021.13.5.697.
7
Asthma and COVID-19 risk: a systematic review and meta-analysis.哮喘与 COVID-19 风险：系统评价和荟萃分析。
Eur Respir J. 2022 Mar 31;59(3). doi: 10.1183/13993003.01209-2021. Print 2022 Mar.
8
Asthma and COVID-19: a dangerous liaison?哮喘与2019冠状病毒病：危险关联？
Asthma Res Pract. 2021 Jul 15;7(1):9. doi: 10.1186/s40733-021-00075-z.
9
Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?回复：Kow CS等人。重症哮喘患者发生COVID-19严重后果的风险更高吗？
Allergy. 2021 Mar;76(3):961-962. doi: 10.1111/all.14593.
10
Asthma in patients with coronavirus disease 2019: A systematic review and meta-analysis.2019 冠状病毒病患者的哮喘：系统评价和荟萃分析。
Ann Allergy Asthma Immunol. 2021 May;126(5):524-534. doi: 10.1016/j.anai.2021.02.013. Epub 2021 Feb 18.
慢性呼吸道疾病或其治疗是否会影响感染SARS-CoV-2的风险？
Lancet Respir Med. 2020 May;8(5):436-438. doi: 10.1016/S2213-2600(20)30167-3. Epub 2020 Apr 3.
4
Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy.意大利新冠肺炎死亡患者的病死率及特征
JAMA. 2020 May 12;323(18):1775-1776. doi: 10.1001/jama.2020.4683.
5
Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.合并症的患病率及其对 SARS-CoV-2 感染患者的影响：系统评价和荟萃分析。
Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.
6
Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.格隆溴铵、福莫特罗和布地奈德对人鼻和气管上皮细胞原代培养物中冠状病毒HCoV-229E复制及细胞因子产生的抑制作用。
Respir Investig. 2020 May;58(3):155-168. doi: 10.1016/j.resinv.2019.12.005. Epub 2020 Feb 21.
7
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.中国武汉 140 名 SARS-CoV-2 感染患者的临床特征。
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
8
Role of viruses in asthma.病毒在哮喘中的作用。
Semin Immunopathol. 2020 Feb;42(1):61-74. doi: 10.1007/s00281-020-00781-5. Epub 2020 Jan 27.
9
Respiratory health and disease in Europe: the new European Lung White Book.欧洲的呼吸健康与疾病：新的《欧洲肺部白皮书》
Eur Respir J. 2013 Sep;42(3):559-63. doi: 10.1183/09031936.00105513.
10
The prevalence of asthma and COPD in Italy: a practice-based study.意大利哮喘和 COPD 的流行情况：一项基于实践的研究。
Respir Med. 2011 Mar;105(3):386-91. doi: 10.1016/j.rmed.2010.09.022. Epub 2010 Oct 15.